New information concerning anesthesia and surgery for the morbidly obese patient

DURING the past 6 years, 126 patients with Hodgkin's disease have been treated adequately with Vinblastine. All patients either presented with Stage III or IV disease (Rye classification) or have developed recurrent disease after radiotherapy has been given previously for more localised disease. Most of the patients have had systemic manifestations. Although a rapid response to Vinblastine is frequently seen, a few patients who are going to respond do so slowly over a period of 3-4 weeks. For this reason patients who have received less than 4 weeks' treatment have been excluded from the report because the treatment has been inadequate.